@article{a9aefb7d3b814136ab525013efd69289,
title = "Paclitaxel in the treatment of carcinosarcoma of the uterus: A Gynecologic Onclogy Group study",
abstract = "Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. Methods. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m2 (135 mg/m2 in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy. Results. A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38-79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1-18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect. Conclusions. Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus.",
author = "Curtin, {John P.} and Blessing, {John A.} and Soper, {John T.} and Koen DeGeest",
note = "Funding Information: 1This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517). The following Gynecologic Oncology Group institutions participated in this study: University of Alabama at Birmingham, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University School of Medicine, Emory University Clinic, Colorado Foundation for Medical Care, Hospital of the University of Pennsylvania, The Milton S. Hershey School of Medicine of the Pennsylvania State University, University of Cincinnati College of Medicine, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Health Science Center at Dallas, Indiana University Medical Center, Bowman Gray School of Medicine of Wake Forest University, The Albany Medical College of Union University, Rush–Presbyterian–St. Lukes Medical Center, State University of New York Downstate Medical Center, University of Kentucky, Eastern Virginia Medical School, Pennsylvania Hospital, Washington University School of Medicine, Cooper Hospital University Medical Center, Columbus Cancer Council, University of Massachusetts Medical Center, Fox Chase Cancer Center, University of Oklahoma Health Science Center, University of Virginia Health Science Center, Tacoma General Hospital, Mayo Clinic, and Case Western Reserve University.",
year = "2001",
doi = "10.1006/gyno.2001.6256",
language = "English (US)",
volume = "83",
pages = "268--270",
journal = "Gynecologic oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",
}